Observational Study for Transthyretin Amyloidosis
(ConTTRibute Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to study ATTR amyloidosis, a condition where abnormal proteins accumulate in the body and cause damage. Researchers seek to understand the progression of this condition and evaluate the effectiveness of two treatments, patisiran and vutrisiran (both RNA interference therapies), in real-world settings. They also aim to track individuals with the genetic marker for the condition who do not yet show symptoms. Suitable candidates for this trial include those diagnosed with ATTR amyloidosis or those carrying the gene known to cause it, but who cannot participate in another clinical trial simultaneously. As a Phase 2 trial, this research focuses on assessing the treatment's effectiveness in an initial, smaller group, offering participants a chance to contribute to important early findings.
Do I have to stop taking my current medications for this trial?
The trial protocol does not specify if you need to stop taking your current medications. However, if you are in Germany, you must be treated according to the approved treatment guidelines for ATTR amyloidosis.
Why are researchers excited about this trial?
Researchers are excited about the ConTTRibute observational study because it offers a comprehensive look at patients with Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis) worldwide, which can provide valuable insights into the progression and management of this condition. Unlike treatments that focus solely on managing symptoms, this study aims to gather real-world data that could lead to better understanding of disease patterns and patient outcomes. By collecting and analyzing this data, researchers hope to improve future treatment strategies and potentially uncover new therapeutic targets, ultimately enhancing patient care.
Who Is on the Research Team?
Medical Director
Principal Investigator
Alnylam Pharmaceuticals
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Observational Study
Participants are observed to describe epidemiological and clinical characteristics, natural history, and real-world clinical management of ATTR amyloidosis patients
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Observational Study
Find a Clinic Near You
Who Is Running the Clinical Trial?
Alnylam Pharmaceuticals
Lead Sponsor
Dr. Yvonne Greenstreet
Alnylam Pharmaceuticals
Chief Executive Officer since 2021
MD from the University of Leeds, MBA from INSEAD
Dr. Pushkal Garg
Alnylam Pharmaceuticals
Chief Medical Officer since 2016
MD from Columbia University
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.